Skip Ribbon Commands
Skip to main content
Sign In

24944 Drug of Abuse, Behavioral Health, Urine

Drug of Abuse, Behavioral Health, Urine
Test Code: BHDAS
Synonyms/Keywords
​amphetamines, benzodiazepines, cannabinoids, cocaine, opiates, oxycodone, Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Marijuana, THC, Benzoylecgonine, Cocaine, Hydromorphone, Hydrocodone, Morphine, Codeine, Oxymorphone, Oxycodone, Oxycontin, Vicodin, Date Rape Drug, 7-Aminoflunitrazepam, Roofies, Rohypnol, Amines
Test Components
​Immunoassay screen quantitative confirmation by gas or liquid chromatography methods (when needed) for the following drug classes or method groups:  amphetamines, benzodiazepines, cannabinoids, cocaine, opiate method group, and oxycodone method group.  Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
 
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well.  If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present.
Useful For
​ The detection of drug classes listed in this survey is useful for compliance monitoring and identification of abuse. 
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
No​ Urine​ Sage urine collection container​ Sterile plastic container with no preservatives​ 10 mL​ 8 mL​ 5 mL​
Specimen Stability Information
Specimen Type Temperature Time
Urine​ Refrigerate (Preferred)​ 30 days​
Ambient​ 7 days​
Frozen​ 30 days​
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Marshfield Monday through Friday​
If no confirmatory work is required:
1 day​
 
If confirmatory work is required:
4 days
Beckman AU680 Clinical Chemistry System with Emit Immunoassay and Gas Chromatography-Mass Spectrometry (GCMS) using Selected Ion Monitoring and/or Liquid Chromatography/Tandem Mass Spectrometry (LCMS/MS) using Multiple Reaction Monitoring (if needed for confirmation)​
Test Information
This test was developed and its performance characteristics determined by Marshfield Labs. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity testing.
 
This test is designed to support medical, not forensic, purposes. The detection of drugs listed in this survey is to be used for compliance monitoring and identification of abuse.
 
This test uses immunoassy methods to first screen for the following drug classes or method groups: amphetamines, benzodiazepines, cannabinoids, cocaine, opiate method group, and oxycodone method group at and above cut-off levels. If the screen is positive, this test also includes GCMS or LC/MS/MS confirmation.  Also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
 
All confirmations / quantitations are charged separately as needed.
The amphetamine class includes phentermine, amphetamine, methamphetamine, ephedrine, pseudoephedrine, MDA, MDEA and MDMA (Ecstasy).
 
Benzodiazepines class includes desalkylflurazepam, nordiazepam, 7-aminoflunitrazepam, oxazepam, temazepam, 7-aminoclonazepam, lorazepam, alpha-hydroxyalprazolam, and diazepam.
 
Opiate method group includes morphine, codeine, hydrocodone, hydromorphone.
 
Oxycodone method group includes oxycodone and oxymorphone.
 
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well.  If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present.
Reference Range Information
Performing Location Reference Range
​Marshfield Negative.  Positives are reported with a quantitative GCMS or LCMS/MS result.​
Interpretation

Current Cutoff Levels for Toxicology

For detailed interpretation information of each drug class/group, please refer to the individual confirmatory assay test codes.

Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
80307​ 1 Single Drug Class Screen​
80359​ ​1 ​Methylenedioxyamphetamines (MDA, MDMA) ​If needed
80326 1​ Amphetamines confirmation ​If needed
​G0480 ​1 ​Amphetamines confirmation ​For Medicare/Medicaid (if needed)
80346 1​ Benzodiazepine confirmation ​​If needed
​G0480 ​1 ​Benzodiazepine confirmation ​For Medicare/Medicaid (if needed)
80349 1​ Cannabinoids confirmation ​​If needed
​G0480 ​1 ​Cannabinoids confirmation ​For Medicare/Medicaid (if needed)
80353 1​ Cocaine confirmation ​​If needed
​G0480 ​1 ​Cocaine confirmation ​For Medicare/Medicaid (if needed)
80361 1​ Opiate confirmation ​​If needed
​G0480 ​1 ​Opiate confirmation ​For Medicare/Medicaid (if needed)
80365​ 1​ Oxycodone confirmation ​ ​​If needed
​G0480 ​1 ​Oxycodone confirmation ​For Medicare/Medicaid (if needed)
Classification
This test was developed and its performance characteristics determined by Marshfield Labs. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity testing.
Synonyms/Keywords
​amphetamines, benzodiazepines, cannabinoids, cocaine, opiates, oxycodone, Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Marijuana, THC, Benzoylecgonine, Cocaine, Hydromorphone, Hydrocodone, Morphine, Codeine, Oxymorphone, Oxycodone, Oxycontin, Vicodin, Date Rape Drug, 7-Aminoflunitrazepam, Roofies, Rohypnol, Amines
Test Components
​Immunoassay screen quantitative confirmation by gas or liquid chromatography methods (when needed) for the following drug classes or method groups:  amphetamines, benzodiazepines, cannabinoids, cocaine, opiate method group, and oxycodone method group.  Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
 
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well.  If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present.
Ordering Applications
Ordering Application Description
​Centricity ​Drug of Abuse, Behavioral Hlth-Urine
​Cerner ​None
​COM ​DAU-Behavioral Health Survey
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
No​ Urine​ Sage urine collection container​ Sterile plastic container with no preservatives​ 10 mL​ 8 mL​ 5 mL​
Specimen Stability Information
Specimen Type Temperature Time
Urine​ Refrigerate (Preferred)​ 30 days​
Ambient​ 7 days​
Frozen​ 30 days​
Useful For
​ The detection of drug classes listed in this survey is useful for compliance monitoring and identification of abuse. 
Test Components
​Immunoassay screen quantitative confirmation by gas or liquid chromatography methods (when needed) for the following drug classes or method groups:  amphetamines, benzodiazepines, cannabinoids, cocaine, opiate method group, and oxycodone method group.  Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
 
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well.  If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present.
Reference Range Information
Performing Location Reference Range
​Marshfield Negative.  Positives are reported with a quantitative GCMS or LCMS/MS result.​
Interpretation

Current Cutoff Levels for Toxicology

For detailed interpretation information of each drug class/group, please refer to the individual confirmatory assay test codes.

For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Marshfield Monday through Friday​
If no confirmatory work is required:
1 day​
 
If confirmatory work is required:
4 days
Beckman AU680 Clinical Chemistry System with Emit Immunoassay and Gas Chromatography-Mass Spectrometry (GCMS) using Selected Ion Monitoring and/or Liquid Chromatography/Tandem Mass Spectrometry (LCMS/MS) using Multiple Reaction Monitoring (if needed for confirmation)​
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
80307​ 1 Single Drug Class Screen​
80359​ ​1 ​Methylenedioxyamphetamines (MDA, MDMA) ​If needed
80326 1​ Amphetamines confirmation ​If needed
​G0480 ​1 ​Amphetamines confirmation ​For Medicare/Medicaid (if needed)
80346 1​ Benzodiazepine confirmation ​​If needed
​G0480 ​1 ​Benzodiazepine confirmation ​For Medicare/Medicaid (if needed)
80349 1​ Cannabinoids confirmation ​​If needed
​G0480 ​1 ​Cannabinoids confirmation ​For Medicare/Medicaid (if needed)
80353 1​ Cocaine confirmation ​​If needed
​G0480 ​1 ​Cocaine confirmation ​For Medicare/Medicaid (if needed)
80361 1​ Opiate confirmation ​​If needed
​G0480 ​1 ​Opiate confirmation ​For Medicare/Medicaid (if needed)
80365​ 1​ Oxycodone confirmation ​ ​​If needed
​G0480 ​1 ​Oxycodone confirmation ​For Medicare/Medicaid (if needed)
Classification
This test was developed and its performance characteristics determined by Marshfield Labs. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity testing.
For most current information refer to the Marshfield Laboratory online reference manual.